Knowledge of the pathogenetic mechanisms in facioscapulohumeral muscular dystrophy is still scattered, but has recently been advanced through novel developments on the genetic scientific front.
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is increasingly recognized as one of the most common muscular dystrophies and can still be defined best as an autosomal dominant myopathy with onset in the facial and shoulder girdle muscles and a progressive course with a descending order of muscle involvement in the majority of patients. Emphasis has always been put on the asymmetry of muscle involvement and the variability in age at onset and rate of progression, even within families. More than 95% patients carry a deletion of the 3.3 kb tandem repeat D4Z4 at 4q35, characterized with the probe p13 E-11 on EcoRI digested DNA. The deletion is pathogenic only when it is hypomethylated and resides in an A161 allele. How it brings about its phenotypic effect is currently unclear.
When the genetic defect was established, sporadic cases (new mutations), multiple affected sibs of nonaffected parents (germ-line mosaicism), severe childhood disease with a minimally affected parent (mosaics) and families with a mild course of the disease were embraced in the entity of FSHD. The literature saw several descriptions of unusual manifestations.
The tendency in recent years is to discuss severe, moderate and mild disease and relate these endophenotypes to residual repeats in order to sketch a clinical course and to structure patient management.
Although rarely discussed in detail, severe disease is usually taken as lower limb involvement or wheelchair dependency. Duration of the disease is often not considered, although this says something about the aggressiveness of the disease process. The former concept is a retrospective one, describing the present disability, and the latter implies the future course. However, prognosis has not been studied in detail. Therefore, we rest with the present categories.
(1) Severe disease, infantile form, onset usually before the age of 10 years with one to three residual D4Z4 repeats.
(2) Moderate disease or classical phenotype with four to seven repeats and with a widely variable course, encompassing a large percentage of asymptomatic carriers older than 50 years, and 60% lower limb involvement with 20% wheelchair use after this age. (3) Mild disease with 8-10 residual D4Z4 repeats, probably with frequent nonpenetrant gene carriers and muscle involvement limited to the upper limbs. The latter category has not been explored in sufficient detail. The proportion of occurrence of the three categories is probably not related to the number of residual repeats.
Clinical studies
An epidemiological study from Padua, Italy, demonstrated a prevalence of 1 : 22 000, which is close to the estimate we made in the Netherlands [1]. Sleep quality was reported to be frequently abnormal, which led to sleep registration in 51 consecutive patients [2] . This study showed abnormal respiratory patterns in 40% and sleep apnoea in 3% necessitating nocturnal respiratory support. The relationship, though weak, appears largely mechanic but is another argument for involvement of oro-pharyngeal muscles. Duration and severity of the disease did not appear to be of influence [3,4].
Trevisan et al. [5] confirmed that (high-tone) hearing loss does not occur more frequently in FSHD than in the general population. However, four of their six infantile onset cases had severe hearing loss and also mental retardation and two had epilepsy [6] . Although it is uncertain whether mental retardation in FSHD occurs more frequently than in the general population, so far it has been described only in relation to the infantile form of FSHD.
Respiratory function and ventilation muscle strength were reported to be slightly reduced in FSHD. The authors tied no specific advice to these observations, contrasting previous publications recommending respiratory function tests in wheelchair dependent patients, particularly if they suffered intrinsic pulmonary disease [7] .
Pain was confirmed to be a frequent (70-80%) symptom in FSHD [8] . Although previous studies reported patterns comparable with the muscles involved, Miro et al. [9] specifically mentioned a high frequency of low back pain.
Several studies have appeared on muscle fatigue in FSHD [10, 11] . Severe fatigue [checklist individual strength (CIS) 335] was reported in 51% patients with no increase of central or peripheral fatigue compared with controls, but with an increased frequency of central activation failure. Reduced motivation, concentration, pain and disturbed sleep were suggested mechanisms. Training was proposed as a method to break the vicious cycle of reduced physical activity and experienced fatigue.
The need for biomarkers in FSHD spawned a study into quantification of magnetic resonance (MR) signals for fatty transformation of muscle. Longitudinal studies are necessary to demonstrate the rate of changes over time to prove applicability for clinical trials. Increased intensities found with turbo inversion recovery magnitude (TIRM)sequences were related to oedema and possible inflammation of muscle [12 ] .
DNA-diagnostics
After the demonstration of the D4Z4 deletions on 4q35 as a causative mechanism for the development of FSHD in the majority of patients, it was found that the 4q telomere in the general population exists in two equally observed allelic forms, A and B, but that FSHD occurs in the A allele only. Although the A and B probes reside distally to the repeat, a proximally located polymorphism allowed a further allele distinction that proved only allele A161 being associated with FSHD [13 ]. Furthermore, the residual short repeat in FSHD was found to be hypomethylated, whereas hypomethylation was also found in phenotypical FSHD without a D4Z4 deletion.
A routine Southern blot with probe p13E-11 on EcoRIdigested DNA might lead to false positive conclusions due to nonpathogenic contractions (10%) of a homologous D4Z4 repeat on 10q26, or to nonpathogenic allelism (B-type). Deletions including p13E-11 or hypomethylated normal repeats will give rise to false negative results.
Double digestion with EcoRI and Bln will eliminate the chromosome 10 repeat but might lead to false positive results due to hybrid repeats on chromosome 4.
These uncertainties require reflection of the clinician: if the DNA is sent for confirmation and no small fragment is observed, a muscle biopsy has to be performed to rule out the differential diagnosis of the FSH-syndrome before proceeding to allelic typing and methylation studies. If the DNA is sent for exclusion and a small 4-type fragment is obtained, pulsed field gel electrophoresis with triple digestion and allelic typing is indicated.
Genes, genetic mechanisms and pathways
As soon as the deleted D4Z4 repeat was confirmed as the causative mechanism of FSHD, the search for expressed sequences of the repeat was initiated in several laboratories.
Although the repeat contains an open reading frame (DUX4), a double homeo domain and a weak promoter, no transcript could be obtained by various techniques and in different substrates.
Assuming a position effect in cis, genes proximal to the repeat, FRG2 (35 kb), FRG1 (120 kb) and ANT1 (3.5 Mb) were identified. Gabellini et al. [14] demonstrated repeat size and distance related upregulation of these genes and found in a subsequent study a muscular dystrophy in mice overexpressing FRG1, but not in mice overexpressing FRG2 or ANT1.
Various attempts with different techniques failed to confirm the FRG1 upregulation. Recent studies in Xenopus laevis showed that FRG1 is essential for angiogenesis and that upregulation disrupts skeletal muscle and vascular development, resulting in increased vascular branching, dilatation and oedema. These observations connect to an earlier expression profiling study in FSHD and link the retinal vasculopathy of FSHD to muscle pathology [15 ] .
More recently, however, D4Z4 mRNA and protein transcripts were reported, probably using a polyadenylation site in pLAM, a sequence distal to D4Z4 and restricted to the A allele. The D4Z4 was described to interact with the promoter of PITX1, leading to an upregulated transcript in accordance with previous studies. PITX1 is a homeoprotein involved in hind-limb development, left-right (a)symmetries and inflammatory cell response [16 ] .
Pathogenetic mechanisms
As most genetic mechanisms of diseases involve transcriptional dysregulation, this broad term is somewhat meaningless. In the present review, we will discuss some factors involved in transcriptional control that might be relevant for FSHD.
Although most human telomeres localize to the nucleus' interior, the 4q telomere attaches to the nuclear lamina in patients and controls. This attachment appears emerin and lamin A/C dependent. The D4Z4 repeat contains CTCF biding sites and it was suggested that the contracted repeat acts as a lamin A and CTCF dependent insulator allowing expression of FSHD genes [17 ] .
Similarly, Gabellini et al. reported D4Z4 binding to a repressor complex consisting of YY1 (transcriptional repressor), high mobility group box 2 (HMGB2) and nucleolin, and suggested that a D4Z4 deletion leads to diminished repression allowing transcription of genes in cis at short distances.
We demonstrated hypomethylation of the contracted repeat and hypomethylation of a normal length repeat in FSHD phenocopies. Its role in FSHD pathogenesis is unclear at present.
Histone H3 methylation at lysine 4 and histone H4 acetylation at lysine 8 do not appear different in patients and controls and suggested an unexpressed euchromatin rather than a heterochromatin structure [18 ] . In addition, loss of H3K9 trimethylation of D4Z4 was found to be specific for both forms of FSHD and this was related to loss of HP1 and cohesion binding in a tissue (muscle) specific manner leading to derepression of transcription [19 ] .
The discovery of a nuclear scaffold/matrix attached region (S/MAR) proximal to the D4Z4 repeat led to the demonstration of an alteration of the 3D-structure of 4q35 in FSHD myoblasts and the formation of a single chromatin loop domain instead of a double loop [20] . The change in chromatic accessibility was suggested to influence transcription in cis. Then results were extended in a subsequent study demonstrating interaction between the 4q A/B markers/region and FRG1 and ANT1 promoters in FSHD myoblasts [21] . A transcriptional enhancer element was demonstrated in the 4qA allele and a more complicated loop model of the 4q telomere was proposed. How this all fits together is at present unclear. Several models appear to be teleological constructs waiting for the advancement of the genetic scientific front [21] .
Pathways implicated in the pathogenetics of facioscapulohumeral muscular dystrophy
When a classical genetic approach in FSHD seemed to fail, microarray techniques were explored. Early studies indicated upregulation of genes involved in mitochondrial metabolism, cell-cycle control and myogenesis. These results were interpreted as in line with earlier studies showing slowed and poor development of FSHD myoblasts in cultures related to increased susceptibility to oxidative stress. Surprisingly none of these, nor later array studies, showed upregulation of FRG1, and no or only minimal upregulation of ANT1.
A RNA profiling study comparing profiles of muscle biopsies from 10 different myopathies found the laminopathies most closely resembling FSHD, which does not come as a surprise to clinicians who remember the first Emery-Dreifuss families reported as scapuloperoneal muscular dystrophy with contractures, cardiomyopathy and occasionally facial weakness [22] .
A recent RNA microarray study in vastus lateralis biopsies showed, after filtering out genes dysregulated in other muscular dystrophies, 84 downregulated and 44 upregulated genes, of which several of the latter were involved in vascular smooth muscle and endothelial cell biology [15 ] . These results were stressed in the light of the frequent presence of perivascular infiltrates in FSHD biopsies and retinal vasculopathy on fluorescent angiography. This study did not show upregulation of FRG1, which makes it difficult to connect to the recent studies of FRG1 function in tadpoles demonstrating its role in muscle and micro-vascular development [23 ,24 ] .
Conclusion
In sum, research in the pathogenesis of FSHD appears to find some firm ground but at present it is unclear how all findings fit together. The overall picture points to major involvement of muscle development pathways and, possibly, vascular development pathways as well. This feeds into ideas about homeobox-related transcriptional dysregulation, which was originally suggested, based on Facioscapulohumeral muscular dystrophy Padberg and van Engelen 541 the apparent descending order of spread of muscle weakness. Also, the not-infrequent misdiagnosis of Moebius syndrome in infantile onset cases and the frequent occurrence of pectus excavatum agree with this line of thinking. All these observations set a broad agenda for further research and possible therapeutic targets.
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